Our Company
About Us
About Xanamem
®
Our Team
Recent Annual Reports
Our Strategic Priorities
Corporate Governance
Xanamem
®
The Cortisol Hypothesis
Mechanism of Action
Publications
Clinical Trials
Clinical Development Pipeline
Cognitive Impairment in early Alzheimer’s Disease
Cognitive Impairment in MDD
Anxiety, sleep & behavioral problems in Fragile X Syndrome
Patient Portal
Participate in clinical trials
The XanaCIDD Depression Clinical Trial
The XanaMIA Phase 2b Alzheimer’s Trial
Publications
Investor Centre
Share Price
ASX Announcements
Corporate Presentations
Analyst Reports
Financial Results Centre
Annual General Meeting
General Meeting
Financial Calendar
Right to Receive Documents
Frequently Asked Questions
Investor Contacts
News
Contact Us
News
Latest Summary Corporate Presentation
November 2023
View Presentation
All updates and Media
Media
Corporate Presentations
10 Oct 2022
The Motley Fool
Guess which ASX biotech share just rocketed 56% on new Alzheimer’s drug trial results
10 Oct 2022
Market Screener
Actinogen Medical Validates Efficacy of Alzheimer’s Disease Therapy; Shares Surge 30%
10 Oct 2022
ShareCafe
Stocks of the Hour: HLX, ACW, GAL
10 Oct 2022
Market Index
Actinogen up 30% on strong Alzheimer’s trial results, says Xanamem product can slow progression
10 Oct 2022
Actinogen
Company presentation: Alzheimer’s Disease biomarker study clinical results – Large clinical benefit on FDA-approved measurement of cognition and function in patients with Alzheimer’s Disease
10 Oct 2022
PR Newswire
Actinogen Medical Limited (ACW) announces large Xanamem therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
29 Sep 2022
Stocks Down Under
Actinogen Medical (ASX: ACW): Good news on phase 2 trials can catapult this stock
13 Sep 2022
Actinogen
Company presentation: Xanamem® Clinical Program Update – Alzheimer’s Disease (AD) biomarkers – context and history
11 Aug 2022
Actinogen
Company presentation: CEO presentation for non-deal roadshow investor meetings
03 Aug 2022
Actinogen
Webcast video recording: Actinogen Clinical Trials Science Forum
03 Aug 2022
Actinogen
Company presentation: Actinogen Clinical Trials Science Forum
28 Jul 2022
Actinogen
Company presentation: CEO presentation to Spark Plus Australian Equities Day
14 Jul 2022
Mirage News
Actinogen confirms Alzheimer’s disease biomarker study timing and design
27 Jun 2022
FN Arena
Australian Broker Call *Extra* Edition – Jun 27, 2022 | Bell Potter initiates coverage on Australian drug developer Actinogen Medical
14 Jun 2022
Actinogen
Company presentation: CEO presentation for meetings at BIO International Convention
14 Jun 2022
The Market Herald
Actinogen Medical (ASX:ACW) announces phase two trial designs for AD & MDD
14 Jun 2022
Biotech Daily
Actinogen Medical Plans Xanamem For Alzheimer’s, Depression Phase II Trials
14 Jun 2022
The Sentiment
Why one contentious FDA drug approval is good news for Actinogen Medical
14 Jun 2022
IQ Stock
Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022
Global Newswire
Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022
Yahoo Finance
Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
14 Jun 2022
Biospace
Actinogen Announces Phase 2 Trials in Alzheimer’s Disease and Depression
11 May 2022
Actinogen
Company presentation: Bioshares Biotech Summit 2022
04 May 2022
Actinogen
Company presentation: ACW trial results & strategic update presentation
04 May 2022
The Market Herald
Actinogen (ASX:ACW) prioritises Alzheimers disease and depression trials
04 May 2022
Market Index
Actinogen reassesses its priorities: Clinical programs refocus on cognition
02 May 2022
Aged Care Insite
Is Xanamem the Alzheimer’s breakthrough we’ve all been waiting for?
28 Apr 2022
Eminetra Australia
Positive test results for Alzheimer’s drug Xanamem
28 Apr 2022
TechInvest
Actinogen announces positive XanaMIA Part A trial
28 Apr 2022
Aged Care News
Millions could benefit after breakthrough Alzheimer’s treatment trial by Aussie biotech
28 Apr 2022
Hospital and Healthcare
Positive trial results for Alzheimer’s drug Xanamem
27 Apr 2022
Actinogen
Webcast video recording: XanaMIA Part A Trial positive topline results for Xanamem
27 Apr 2022
Biotech Daily
Actinogen XanaMIA Phase 1B Part A Trial Meets Endpoints
27 Apr 2022
The Sentiment
New trial results from Actinogen hold promise for Alzheimer’s treatment
27 Apr 2022
The Market Herald
Actinogen Medical (ASX:ACW) reports positive XanaMIA Part A trial topline results
27 Apr 2022
Kalkine Media
Actinogen gets upbeat results from Xanamem trial for Alzheimer’s treatment
27 Apr 2022
Mirage News
Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s
27 Apr 2022
Actinogen
Company presentation: XanaMIA Part A Trial positive topline results for Xanamem
27 Apr 2022
Australian Associated Press
Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022
news.com.au
Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022
The Australian
Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s
27 Apr 2022
The National Tribune
Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s
27 Apr 2022
Actinogen
Media Release: Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s by Aussie biotech Actinogen
26 Apr 2022
Clinical Trials Arena
Pipeline Moves: Actinogen makes strides in mild cognitive impairment
01 Mar 2022
Actinogen
Company presentation: CEO presents at Sachs 15th Annual European Life Sciences Conference
11 Feb 2022
The Market Herald
Actinogen Medical (ASX:ACW) advances Alzheimer’s treatment
09 Feb 2022
The Sentiment
Actinogen appoints leading researchers to conduct Phase 2 trials for treatment of Fragile X Syndrome
09 Feb 2022
The Market Herald
Actinogen Medical (ASX:ACW) locks in trial manager for FXS phase-two study
09 Feb 2022
Biotech Daily
Worldwide To Manage Xanamem Fragile X Trial
10 Jan 2022
Actinogen
Company presentation: CEO presents at San Francisco Healthcare Conference
Load more
Back
to top